Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Alecensaro Alectinib Locally advanced or metastatic ALK+ NSCLC (first line) Reimburse with clinical criteria and/or conditions Complete
Alecensaro Alectinib Non-Small Cell Lung Cancer Do not reimburse Complete
Alecensaro alectinib ALK-positive NSCLC Active
Alimta Pemetrexed Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Reimburse with clinical criteria and/or conditions Complete
Aloxi (capsule) Palonosetron hydrochloride Chemotherapy-induced nausea and vomiting Do not list Complete
Aloxi (capsule) Palonosetron Chemotherapy-induced nausea and vomiting Withdrawn
Aloxi (injection) Palonosetron hydrochloride Chemotherapy-induced nausea and vomiting Do not list at the submitted price Complete
Alsitek masitinib mesylate Amyotrophic lateral sclerosis (ALS) Suspended
Altace HCT Ramipril/hydrochlorothiazide Hypertension Cancelled
Altace HCT Ramipril/hydrochlorothiazide Hypertension List Complete
Altace Plus Felodipine Ramipril/felodipine extended release Hypertension Do not list Complete
Alunbrig Brigatinib NSCLC Do not reimburse Complete
Alunbrig Brigatinib (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) Reimburse with clinical criteria and/or conditions Complete
Alvesco Ciclesonide asthma List Complete
Amevive Alefacept Psoriasis, moderate to severe chronic plaque Do not list Complete
Amevive Alefacept Psoriasis, moderate to severe chronic plaque Do not list Complete
Amvuttra vutrisiran Hereditary transthyretin mediated amyloidosis (hATTR amyloidosis) Reimburse with clinical criteria and/or conditions Complete
Anoro Ellipta Umeclidinium/vilanterol Chronic obstructive pulmonary disease List with criteria/condition Complete
Apidra Insulin glulisine Diabetes, Mellitus (Type 1 & 2) List in a similar manner to other drugs in class Complete
Apprilon Doxycycline monohydrate Rosacea Do not list Complete
Apretude cabotegravir HIV-1 infection, pre-exposure prophylaxis Active
Aptiom Eslicarbazepine acetate Epilepsy, partial-onset seizures List with criteria/condition Complete
Aptivus Tipranavir HIV infection List with clinical criteria and/or conditions Complete
Arbesda RespiClick fluticasone propionate / salmeterol xinafoate Asthma Reimburse with clinical criteria and/or conditions Complete
Arnuity Ellipta Fluticasone furoate Asthma List with criteria/condition Complete